MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion Criteria: 54-Week Base Study: Patients between the ages of 18 and 78 with Type 2 Diabetes Mellitus (a specific type of diabetes) 50-Week Extension Study: Patients who complete the 54-week base study are eligible to enter the 50-week extension study Exclusion Criteria: Patients who do not have Type 2 Diabetes Mellitus (a specific type of diabetes)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Active Comparator
Active Comparator
Experimental
Experimental
Placebo Comparator
Experimental
1
2
3
4
5
6
7
MK0431 100 mg q.d.
Metformin 500 mg b.i.d.
Metformin 1000 mg b.i.d.
Coadministration of MK0431 and Metformin 50/500 mg b.i.d.
Coadministration of MK0431 and Metformin 50/1000 mg b.i.d.
Placebo/Metformin 1000 mg b.i.d.
Non-Randomized, Open-Label: Coadministration MK0431 and Metformin 50/1000 mg b.i.d.